Aasim Sehbai, MD
Hematology & Oncology · Anniston, ALNPI 1689629602
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,919 of the $30,234 with a category attached, or 62.6%. 60 manufacturers reported payments, led by Novartis at 25.1% of the total.
Across 1,116 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- AstraZeneca$5K
- GSK$2K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Seagen Inc.$1K
- plus $12K from 54 others
Across 24 payments — averaging $6115.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$136K
- E.r. Squibb & Sons, L.L.C.$11K
What the payments were for
- Consulting fees$5,40018%
- Speaking & faculty fees$1751%
- Food & beverage$18,91963%
- Education$9063%
- Gifts$2,2577%
- Other$2,5779%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,234 in reported general payments places this provider in the 85th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 35 | $885,739 |
| Neulasta OnproPegfilgrastim | 128 | $879,253 |
| PromactaEltrombopag Olamine | 64 | $850,178 |
| OpdivoNivolumab | 58 | $787,270 |
| Somatuline DepotLanreotide Acetate | 63 | $575,277 |
| KisqaliRibociclib Succinate | 34 | $543,193 |
| IbrancePalbociclib | 26 | $478,371 |
| FotivdaTivozanib Hcl | 13 | $400,632 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 68 | $394,214 |
| BrukinsaZanubrutinib | 26 | $386,577 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 33 | $360,892 |
| TepmetkoTepotinib Hcl | 13 | $319,096 |
| FruzaqlaFruquintinib | 12 | $307,537 |
| BosulifBosutinib | 21 | $298,893 |
| KeytrudaPembrolizumab | 26 | $288,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Kisqali, Tasigna, Scemblix, Adakveo | $7,599 | $2,225,937163 claims |
| PfizerIbrance, Octagam, Bosulif, Ruxience | $1,007 | $1,283,989134 claims |
| E.r. Squibb & Sons, L.L.C.Opdivo, Sprycel | $1,293 | $1,000,44373 claims |
| AstraZenecaTagrisso, Calquence, Imfinzi | $4,683 | $519,56138 claims |
| AmgenXgeva, Mvasi, Prolia | $975 | $483,017158 claims |
| Beigene USA, Inc.Brukinsa | $72 | $386,57726 claims |
| EMD Serono, Inc.Tepmetko | $82 | $319,09613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $431 | $307,53712 claims |
| MerckKeytruda | $907 | $288,14126 claims |
| Johnson & JohnsonProcrit | $1,346 | $271,825138 claims |
| Astellas Pharma US IncXtandi | $174 | $224,30616 claims |
| Global Blood Therapeutics, Inc.Oxbryta | $174 | $170,12716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Anniston
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.